Evidence map›Paper›PMID 28364362›Full record

ReviewHuman cell2017

Advantages of genome sequencing by long-read sequencer using SMRT technology in medical area.

Kazuma Nakano, Akino Shiroma, Makiko Shimoji, Hinako Tamotsu, Noriko Ashimine, Shun Ohki, Misuzu Shinzato, Maiko Minami, Tetsuhiro Nakanishi, Kuniko Teruya and 2 more

Abstract readReview
In one paragraph

Review in Human cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. A Compact Closed Genome ofPathogens (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Whole Genome Sequencing: Applications in Clinical Bacteriology.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024
    Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kazuma NakanoOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan. nakano@oias.or.jp.ORCID http://orcid.org/0000-0001-9908-6526
Akino ShiromaOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Makiko ShimojiOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Hinako TamotsuOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Noriko AshimineOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Shun OhkiOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Misuzu ShinzatoOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Maiko MinamiOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Tetsuhiro NakanishiOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Kuniko TeruyaOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Kazuhito SatouOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.
Takashi HiranoOkinawa Institute of Advanced Sciences, Uruma, Okinawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PacBio RS II is the first commercialized third-generation DNA sequencer able to sequence a single molecule DNA in real-time without amplification. PacBio RS II's sequencing technology is novel and unique, enabling the direct observation of DNA synthesis by DNA polymerase. PacBio RS II confers four major advantages compared to other sequencing technologies: long read lengths, high consensus accuracy, a low degree of bias, and simultaneous capability of epigenetic characterization. These advantages surmount the obstacle of sequencing genomic regions such as high/low G+C, tandem repeat, and interspersed repeat regions. Moreover, PacBio RS II is ideal for whole genome sequencing, targeted sequencing, complex population analysis, RNA sequencing, and epigenetics characterization. With PacBio RS II, we have sequenced and analyzed the genomes of many species, from viruses to humans. Herein, we summarize and review some of our key genome sequencing projects, including full-length viral sequencing, complete bacterial genome and almost-complete plant genome assemblies, and long amplicon sequencing of a disease-associated gene region. We believe that PacBio RS II is not only an effective tool for use in the basic biological sciences but also in the medical/clinical setting.

Indexed as

AnimalsCommunicable DiseasesDNA MethylationGenomeGenome, BacterialGenome, PlantGenome, ViralHumansSequence Analysis, DNADe novo assemblyExtra-long readsPacBio RS IIStructural variationsTargeted sequencing

Identifiers

PMID28364362
PMCPMC5486853

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.